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Sulnn'lary 
Tumor necrosis factor ot (TNF-ot) is a pleiotropic cytokine triggering cell responses through 
two distinct membrane receptors. Stimulation of leukocyte adhesion to the endothelium is one 
of the many TNF-ot activities and is explained by the upregulation of adhesion molecules on 
the endothelial cell surface.  Human umbilical vein endothelial cells (HUVEC) were isolated, 
cultured, and demonstrated to express both TNF receptor types, TNF-K55 and TNF-R75. Cell 
adhesion to HUVEC was studied using the HL60,  U937,  and MOLT-4 cell lines.  HUVEC 
were activated by either TNF-ot, binding to both TNF-R55  and TNF-K75,  and by receptor 
type-specific agonists, binding exclusively to TNF-R55 or to TNF-K75. The TNF-ot-induced 
cell adhesion to HUVEC was found to be controlled almost exclusively by TNF-R55. This finding 
correlated with the exclusive activity of TNF-K55 in the TNF-ot-dependent regulation of the 
expression of the intercellular adhesion molecule type 1 (ICAM-1), E-selectin, and vascular cell 
adhesion molecule type 1 (VCAM-1). The CD44 adhesion molecule in HUVEC was also found 
to be upregulated through TNF-K55.  However, both TNF-R55 and TNF-R75 upregulate ot2 
integrin expression in HUVEC. The predominant role of TNF-R55 in TNF-ot-induced adhesion 
in HUVEC may correlate with its specific control of NF-xB activation, since xB elements are 
known to be present in ICAM-1,  E-selectin, and VCAM-1  gene regulatory sequences. 
T 
umor necrosis factor (TNF-ot; the term TNF refers to 
TNF-ot and TNF-/~ jointly) was originally discovered 
by its antitumor activity, but is now recognized to be one 
of the most pleiotropic cytokines acting as a host defense factor 
in immunologic and inflammatory responses (1-4). Among 
its many different activities, TNF has effects on the vascular 
endothelium (5, 6) that may contribute to tissue injury in 
pathologies such as the disseminated intravascular coagula- 
tion seen in septic shock or in cerebral malaria, and may in 
part be responsible for the hemorrhagic tumor necrosis in 
animal models (1, 2). TNF-ot triggers endothelial cells to se- 
crete various factors, including PAI-1 (7), IL-1 (8), GM-CSF 
(9), and IL-6 (10). TNF-ot activity also results in phenotypic 
changes of the endothelium characterized by an increased per- 
meability (11) and in the induction or upregulation of var- 
ious cell adhesion molecules such as E-selectin (12), intercel- 
lular adhesion molecule type 1 (ICAM-1) 1 (13), and vascular 
1 Abbreviations used in this pater: EMSA, dectrophoretic  motility  shift assay; 
HUVEC, human umbilical vein endothelial  cells; ICAM-1, intercellular 
adhesion  molecule  type  1; VCAM-1, vascular  cell  adhesion  molecule  type 1. 
cell adhesion molecule type 1 (VCAM-1) (14-16).  The regu- 
lated expression of these adhesion molecules and of their 
counter-receptors on leukocytes mediates the adhesion and 
extravasation of white blood cells during an inflammatory 
reaction (17-20). 
TNF-Ot activity is mediated through at least two distinct 
membrane receptors, the 75-k_D receptor (also termed TNF- 
Rot, TNF-R2, or TNF-R75) and the 55-kD receptor (TNF- 
RB, TNF-R1, or TNF-R55) (21). Both receptors bind TNF-ot 
and TNF-fl with similar affinities (22), but they are indepen- 
dently regulated (23). Their extraceUular domains have similar 
cysteine-rich repeat  motifs  that  are characteristic  for  the 
NGF/TNF receptor gene family (24).  In contrast, their in- 
tracellular domain sequences are entirely unrelated, suggesting 
distinct signal transduction pathways (for reviews see refer- 
ences 25 and 26). Distinct functions for the two TNF receptors 
indeed have been found in previous studies. Specific stimula- 
tion of TNF-K55 mimics TNF-ot activities such as cytotox- 
icity, fibroblast proliferation, resistance to chlamidiae, syn- 
thesis of prostaglandin, and induction of MnSOD mKNA 
(27-30).  In addition,  the presence of TNF-R55  alone on 
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pression (31), and TNF-R55 was reported to control NF-KB 
activation in hemapoietic cell lines (23, 32, 33). Less is known 
about  the specific function of TNF-R75.  It was  found to 
mediate mouse thymocyte proliferation (34). A recent report 
provides evidence that TNF-R75 induces GM-CSF secretion 
in PC60 cell transfectants (35). TNF-R75 was also been de- 
scribed to stimulate human fibroblast, mononuclear cell, and 
NK  cell proliferation (28,  36,  37). 
Here we describe the activities of the two TNF receptor 
types in the induction of cell adhesion to human endothelial 
cells. We report a specific role of TNF-R55 in the induction 
of cellular  adhesion  to  endothelium.  ICAM-1,  E-selectin, 
VCAM-1,  and CD44  are induced through  TNF-R55,  but 
not  through  TNF-R75.  In contrast,  the expression of o~2 
integrin was found to be mediated through TNF-R75  and 
TNF-R55. 
Materials  and Methods 
Cell Lines.  HL60, U937, and MOLT-4 cell lines were obtained 
from the American Type Culture Collection (Rockville, MD). Media 
and usual culture reagents were purchased from Gibco Laborato- 
ries (Grand Island,  NY). HL60 and U937 cells were cultured in 
RPMI  1640,  10% FCS,  2 mM glutamine,  100 U/ml penicillin, 
and 100/zg/ml streptomycin. MOLT-4 cells were cultured in Iscove 
medium, 10% FCS, 2 mM glutamine, 100 IU/ml penicillin,  100 
/zg/ml streptomycin, and 50 mM 2-ME (Fluka Chemie AG, Buchs, 
Switzerland). 
Human  Umbilical Vein Endothelial Cells (HUVEC).  HUVEC 
were purified from human umbilical  cords as detailed by Jaffe et 
al. (38). HUVEC were cultured in medium M199 (Sigma Chem- 
ical Co., St. Louis, MO) supplemented with 20% FCS, 100 U/ml 
penicillin,  100/~g/ml streptomycin, 2 mM glutamine, 2.5/zg/ml 
fungizone (Gibco Laboratories), 20 #g/ml  gentamycine (Gibco 
Laboratories),  100/~g/ml endothelial cell growth factor (ECGF; 
Collaborative Research, Inotech AG, Dottikon, Switzerland), and 
100/~g/ml heparin sodium salt (Sigma Chemical Co.). Culture flasks 
were precoated for I h at ambient temperature with 1% BSA (Sigma 
Chemical Co.) in PBS, then washed once with HBSS (Gibco Labora- 
tories). Cells isolated from different cords were not pooled. HLrVEC 
were used after at least  three passages. Cellular homogeneity in 
the culture was controlled by staining with mouse anti-human Von 
Willebrand factor:FVIII:c/v WF complex antibody (Immunotech 
SA, Marseille,  France). 
Reagents.  Mouse mAbs to TNF-R55 (htr-9, htr-5, htr-1, htr- 
20) and to TNF-R75 (utr-1) have been described  previously (26, 
39). IgG antibodies were purified from hybridoma supernatants 
on a protein G-Sepharose column (Pharmacia LKB Biotechnology, 
Uppsala, Sweden).  IgM antibodies were purified by affinity chro- 
matography using goat anti-mouse Ig (# chain specific) covalently 
attached  to  cyanogen bromide-activated  agarose  beads  (Sigma 
Chemical Co.). Mouse anti-human ICAM-1, anti-human VCAM-1, 
and anti-human E-selectin were purchased from British Biotech- 
nology Products Ltd. (Oxon, UK), mouse anti-human MHC class 
I from Immunotech SA, mouse anti-human CD44 (F10-44-2) from 
Serotec (Inotech AG), and mouse anti-human integrin molecule 
antibodies from Telios Pharmaceuticals  Inc. (San Diego, CA). Poly- 
clonal anti-TNF receptor antibodies were raised by immunizing 
rabbits with recombinant extracellular regions of human TNF-R75 
or TNF-R55 expressed in the SD/baculovirus system or CHO cells 
as previously described (22). Specific antibodies against TNF-R75 
or TNF-R55 were purified from rabbit antisera by affinity chro- 
matography using CNBr-activated Sepharose 4B (Pharmacia LKB 
Biotechnology) coupled with recombinant soluble TNF-R75 or 
TNF-R55, respectively. The resulting affinity-purified rabbit anti- 
bodies were termed RaTNF-R75 (anti-TNF-R75) and RaTNF-R55 
(anti-TNF-R55). Goat anti-mouse Ig antibodies labeled with PE 
were purchased from Southern Biotechnology Associates Inc. (Bir- 
mingham, AL). Recombinant human TNF-c~ and TNF-ol with 
point mutations at residues 32 and 86, R32W/S86~rFNF-c, (termed 
Trp32 Thr86 TNF), purified from Escherichia coli (Loetscher, H., 
D. Stueber,  D. Banner,  F. Mackay, and W. Lesslauer, manuscript 
in preparation). 
Western Blotting Analysis.  HL60 cells and HUVEC were grown 
to 90%  confluency (~o10  s cells total) and incubated for 2  h  in 
medium at 4~  with 15/zg/ml of htr or utr mAbs.  HL60 cells 
were then harvested and washed twice with PBS. HUVEC were 
detached with trypsin-EDTA under conditions described below (see 
flow cytometry section), and washed twice in PBS supplemented 
with 100 U/ml aprotinin (Trasylol; Bayer, Leverkusen, Germany). 
Cells were resuspended in 0.75 ml PBS containing 1 mM PMSF 
(Sigma Chemical Co.), 100 U/ml aprotinin, 10 mM benzamidine 
(Sigma Chemical Co.), 1 mM orthophenanthroline (Fluka Chemic 
AG), 5 #M leupeptin (Fluka Chemic AG), 1/~M pepstatine (Fluka 
Chemie AG), and 0.1% sodium azide (lysis buffer). 0.75 ml oflysis 
buffer containing 2% Triton X-100 were added and cells were gently 
agitated 90 min at 4~  The lysate was centrifuged 15 min, 70,000 
rpm at 4~  in an ultracentrifuge (TL 100; Beckman Instrs., Inc., 
Fullerton, CA). The supernatant was filtered through a 0.2-/~ filter 
(Acrodisc,  Gelman Sciences, Ann Arbor, MI) and incubated 1 h 
at 4~  under gentle agitation with 50 #1 of protein G-Sepharose 
FF beads (Pharmacia LKB Biotechnology). The beads were washed 
sequentially with  lysis buffer containing  1%  and 0.1%  Triton 
X-100, respectively, and transferred to an ultrafree filter unit (Mil- 
lipore Products Division, Bedford, MA) to drain the buffer. The 
beads were resuspended  in 20/zl of Laemmli sample buffer (40), 
heated for 2 min at 95~  and centrifuged briefly, and the superna- 
tants subjected  to SDS-PAGE.  The proteins were transferred to 
Immobilon-P membranes (Millipore Products Division) and in- 
cubated with 20 ~g/ml of RaTNF-R75 or RaTNF-R55, respec- 
tively, in 50 mM Tris-HC1, pH 7.4, 140 mM NaC1, 5 mM EDTA, 
0.02% NAN3, and 1% dry milk powder at ambient temperature 
over night,  washed,  and incubated with  nSI-labeled goat anti- 
rabbit antiserum (New England Nuclear, Boston, MA) for 3 h at 
ambient temperature.  The membranes were then repeatedly washed 
with PBS, dried, and exposed to an autoradiographic film. 
Flow Cytometry.  HUVEC were detached with trypsin-EDTA 
(Gibco Laboratories) according to the following calibrated protocol. 
When 80% of the cells were detached, the trypsin treatment was 
stopped with 10 volumes of medium containing 20% FCS,  and 
the cells were washed twice with PBS, 0.05%  NAN3,  1% BSA 
(FACS  |  buffer [Becton Dickinson & Co., Mountain View, CA]). 
Cells were incubated 30 min on ice with the respective antibodies 
at 2 #g/ml in FACS  |  buffer, washed once in FACS  |  buffer, and 
incubated 30 min on ice with PE-conjugated goat anti-mouse Ig 
at 5/zg/ml in FACS  |  buffer. Cells were then washed twice with 
FACS  |  buffer and analyzed on a FACScan  |  cytofluorimeter (Becton 
Dickinson & Co.). Cells were gated using forward vs. side scatter 
to exclude dead cells and debris. 
Cell Adhesion Assay.  100/zl of a HUVEC suspension  (2.5-3 
x  10  s cells/ml) was  seeded in a microtiter plate (MTP; Costar 
Corp., Cambridge, MA) in the presence of different concentrations 
of TNF-c~, antibodies,  or Trp32 Thr 86 TNF. The MTP was in- 
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with RPMI 1640 supplemented with 10% FCS, 100 U/ml peni- 
cillin, 100/zg/ml streptomycin, and 2 mM glutamine. The cells 
to be used for adherence were prelabeled overnight with 1 #Ci/106 
cells of methyl-[3H]thymidine  (Amersham, Amersham, England), 
washed twice in medium, and added to the endothelial cells  in 100 
/zl medium per well (1-5  x  106 cells/ml). The MTP was further 
incubated from 30 rain to 2 h at 37~  Nonadherent cells were 
removed using a calibrated centrifugation of the inverted MTP in 
PBS at 50 g for 5 min at ambient temperature (41). Radioactively 
labeled cells specifically  bound to the HUVEC were harvested  with 
cell harvester (LKB Instruments,  Inc., Gaithersburg, MD).  The 
radioactivity  was measured  in a Betaplate  liquid scintiUation  counter 
(Pharmacia LKB Biotechnology). Data are expressed as mean and 
standard deviation of triplicates. 
Nuclear Extracts  and Electrophoretic  Mobility Shift Assay (EMSA). 
Nuclear extracts were prepared as described by Digman et al. (42) 
with minor modifications.  Briefly,  cells  were harvested  and washed 
twice with PBS. 15-20  x  106 cells were resuspended in a hypo- 
tonic lysis  buffer (10 mM Hepes, pH 7.9, 1.5 mM MgC12, 10 mM 
KC1; buffer A) at 4~  After a 20-min incubation on ice, cells  were 
homogenized by 20 strokes with a loose-fitting Dounce homo- 
genizer. Nuclei were collected  by centrifugation (4 rain, 6,500 rpm, 
4~  and nuclear proteins were extracted with three pellet volumes 
of  high salt buffer (20 mM Hepes, pH 7.9, 25% [vol/vol] glycerol, 
0.42 M NaC1, 1.5 mM MgCI2, 0.2 mM EDTA, pH 7.5; buffer 
B). After a 1-h incubation on ice, samples  were centrifuged (5 min, 
6,500 rpm, 4~  and the supernatants were diluted in 3 vol low 
salt buffer (20 mM Hepes, pH 7.9, 20%  [vol/vol] glycerol, 0.1 
M KC1,  0.2 mM EUTA, pH 7.5, 1% NP-40; buffer C). The samples 
were used immediately in EMSA or stored at  -80~  Immedi- 
ately before use, buffers A, B, and C were supplemented with 1% 
of a 1 M  1,4-dithio-Dlcthreitol (DTT; Fluka Chemic AG). For 
EMSA, a synthetic oligonucleotide containing the NF-gB binding 
site was used as a probe (5'CTCAACAGAGGGGACTTTCCG- 
AGAGGCCATCT3'). A corresponding mutated oligonucleotide 
was included as control in the assay (5'CTAACAGAAATTACT- 
TTCCGAGAGGCCATCT3'). About 60,000 cpm of the labeled 
synthetic sequence  vcas incubated with 5/A of  each nuclear extract 
for 45 min at ambient temperature in presence of 2/zg of poty(dI- 
dC) (Pharmacia LKB Biotechnology) and 30/~g BSA (43, 44). 
Results 
TNF Receptor  Expression on HUVEC.  The expression of 
the two TNF receptor types, TNF-R55 and TNF-R75, by 
HUVEC was investigated first by flow cytometry, using the 
htr and utr series of mAbs, respectively (26,  39).  The anal- 
)'sis  was  performed  at  a  stage  when  cultures  were  90% 
confluent after the second passage. The cells were detached 
by trypsin-EDTA treatment, which had been shown in sepa- 
rate experiments not to detectabty affect the surface proteins 
of the HUVEC. Control experiments showed that the cells 
analyzed were entirely Von WiUebrand factor positive, which 
confirmed identity and homogeneity of the HUVEC cul- 
ture. Fig. 1 A  shows that unstimulated HUVEC expressed 
both receptor types, TNF-R75 and TNF-R55. The level of 
expression of both receptors was relatively low, as revealed 
by the parallel  staining of U937 cells,  which express  both 
TNF receptor types with a total of a few thousand TNF 
binding sites per cell  (39). 
Figure  1.  TNF receptor expression on HUVEC and U937 cells. (A) 
Cytofluorimetric  analysis  of HUVEC and U937 cells stained  with anti- 
TNF-R55 mAbs  htr-5 (  .... ), htr-1 (  ......  ), and anti-TNF-R75  mAb utr-1 
(  ....  ) followed  by PE-conjugated  goat  anti-mouse  Ig. An'irrelevant  mAb 
was used  as negative  control (  ). (B) Western  blot analysis  of TNF 
receptor expression  by HUVEC  and HL60  cells. Cells  were  incubated  with 
the respective  utr and htr mAb and solubilized  by detergent.  Immune  com- 
plexes were  purified  with protein  G from  the cell  lysate,  subjected  to elec- 
trophoresis on nonreducing  SDS-PAGE (12% gel)  and transferred  to filter 
membranes. The utr (righ  0 and htr blots (left)  were treated  with RaTNF- 
R75  and  RaTNF-R55, respectively, followed with  12Sl-labeled goat 
anti-rabbit antibody  and exposed to x-ray  film. Specific  receptor bands 
in the autoradiogram  are indicated  with arrows. The contaminating  lower 
molecular mass band is due to protein G. 
The expression  of both TNF receptor types by HUVEC 
was confirmed using the Western blot technique (Fig.  1 B). 
Unstimulated HUVEC were incubated for 2 h with either 
htr-20 (anti-TNF-R55) or utr-1 (anti-TNF-R75) antibodies, 
detached, and solubilized by detergents. Immune complexes 
were precipitated with protein G-Sepharose beads and sub- 
jected to SDS-PAGE. After electrophoresis,  the separated pro- 
teins were transferred to filter membranes, which were then 
incubated with a~nity-purified polyclonal rabbit antibodies 
to TNF-R75 (RaTNF-R75) and to TNF-R55 (RaTNF-R55). 
After washing, the filters were incubated with 12SI-labeled 
goat anti-rabbit Ig and reactive bands were revealed by auto- 
radiography (Fig. 1 B). The specific bands representing TNF- 
R75 and TNF-R55 of  HUVEC were found comigrating with 
similar bands from HL60 cells, which are known to express 
both TNF receptor types (26,  39)  (Fig.  1 B). 
Control of ICAM-1,  E-selectin, and  VCAM-I  Expression 
through TNF-R55 but Not through TNF-R 75.  The modula- 
tion of endothelial adhesion molecules ICAM-1, E-selectin, 
and VCAM-1 by TNF-ol is well documented (12, 13, 45). 
To investigate whether either or both TNF receptors control 
the expression of these cell adhesion molecules, HUVEC were 
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both receptor types, and with receptor type-specific agonists. 
The specific activation of TNF-R55 was achieved using three 
independent reagents: first the agonistic mAb htr-1, second 
the RaTNF-K55 agonistic antibodies, and third a recombinant 
mutant of human TNF-ot, R32W/S86~:FNF-ce  (Trp32 Thr86 
TNF), which binds exclusively to TNF-K55. TNF-R75 ac- 
tivation was achieved with RaTNF-R75 agonistic antibodies. 
To investigate ICAM-1, E-selectin, and VCAM-1 expression, 
HUVEC, activated by the various agents, were detached, im- 
munostained, and analyzed by cytofluorimetry. The cytofluori- 
metric histograms obtained are shown in Fig.  2. Similar to 
previous reports (45),  ICAM-1 was found to be expressed 
on unstimulated HUVEC at relatively high levels, whereas 
E-selectin and VCAM-1 were essentially absent. Stimulation 
of HUVEC with human TNF-o~ triggered the upregulation 
of ICAM-1 and the induction of E-selectin  and VCAM-1 
expression (Fig. 2). The modulation of ICAM-1 and VCAM-1 
expression was detectable after 2 h  of TNF-c~  stimulation 
and reached a sustained maximum level after 6-8 h, contrasting 
with the expression  of E-selectin where induction was max- 
imal 2 h after stimulation and the expression again had declined 
after 10 h. This confirmed a previous report showing a tran- 
sient induction of E-selectin by TNF-ot (15). The upregula- 
tion of ICAM-1 and the induction of VCAM-1 in magni- 
tude and kinetic response  were essentially the same, when 
HUVEC were stimulated through TNF-R55  with Trp32 
Thr86 TNF or with htr-1 antibodies (Fig.  2),  and similar 
results were also obtained with the RaTNF-P,55 antibodies. 
Minor differences between the different agonists in the ex- 
tent of induction were seen, and these might be attributed 
to experimental variation, but it cannot be excluded that the 
dimeric or trimeric nature of the different ligands may also 
play a role (27).  In contrast, stimulation via TNF-R75 did 
not lead to any induction in expression  of E-selectin  and 
VCAM-1, nor to upregulation of ICAM-1 expression,  even 
under conditions where RaTNF-R75 antibodies in other func- 
tional responses of HUVEC displayed full agonistic activity 
(see below). 
TNF-ol-induced CD44 Expression Is under TNF-R55 Con- 
trol.  To study the activity of TNF-ce on CD44 expression 
by the endothelium, HUVEC cultures were first stimulated 
with TNF-ol for various time periods, detached as described 
above, and immunostained with the mouse mAb F10-44-2 
directed to a constant epitope of human CD44  (46).  The 
cytofluorimetric histograms obtained are shown in Fig. 3 A. 
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Figure 2.  Cytofluorimetric  profiles of ICAM-1, E-selectin, and VCAM-1 expression on HUVEC. HUVEC were stimulated  in culture for 2, 4, 
6, and 10 h with 10 ng/ml TNF-c~, 10 ng/ml Trp32 Thr86 TNF, 10 #g/ml htr-1, and 1 #g/ml RaTNF-R75 as indicated. HUVEC were then stained 
for cytofluorimetry  with anti-human  ICAM-1, anti-human  E-selectin, and anti-human VCAM-1 mAbs, followed  by PE-conjugated  goat anti-mouse 
Ig. Relative  cell  numbers  (vertical)  and fluorescence  intensity  on logarithmic  scale  (horizontal)  are presented. (NC) Negative  control; (unst) unstimulated  cells. 
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Figure 3.  Cytofluorimetric profiles of CD44 and MHC class I expres- 
sion in unstimulated and activated HUVEC.  HUVEC were stimulated 
6, 24, 48, and 72 h in culture with 10 ng/ml TNF-cx, washed, stained 
with anti-human CD44 mAb (A), or anti-human MHC class I mAb (B), 
followed by PE-conjugated  goat anti-mouse Ig. HUVEC were also stimu- 
lated 72 h with 10 ng/ml Trp32 Thr86 TNF (1), 1/~g/ml RaTNF-R55 
(2), 10 gg/ml htr-1 (3), and 1/~g/ml RaTNF-R75 (4), stained as described 
above with anti-CD44 (C) and anti-MHC class I (D) mAbs. Relative cell 
numbers (vertical) and fluorescence intensity in logarithmic scale (horizontal) 
are presented.  Unstimulated HUVEC (uns  0 are in black, stimulated cells 
in white. 
CD44 was found expressed on unstimulated HUVEC in a 
heterogenous fashion. The majority of the cells showed no 
or low CD44 expression, but about a third of the cells showed 
higher expression. Interestingly, after 48-72 h of TNF-oL stim- 
ulation,  the profile of CD44  expression was  significantly 
changed, since >50% of the cells were shifted to the CD44 
highly expressing cell population. As a control, MHC class 
I expression was analyzed in parallel cultures (Fig. 3 B). MHC 
class I molecules were expressed on unstimulated HUVEC, 
and upregulated after 24 h of TNF-ot treatment as previously 
reported (47).  It is noteworthy, however, that in contrast to 
the heterogeneous CD44 staining, the same cells showed ho- 
mogeneous staining with respect to MHC class I staining 
(Fig. 3 B). This demonstrates that the wide spectrum of ex- 
pression levels is a specific property of CD44 and not due 
to heterogeneity within the HUVEC population. To define 
the TNF  receptor type  mediating  this  CD44  induction, 
HUVEC were stimulated with predetermined optimal con- 
centrations of the TNF-P,55  agonists Trp32 Thr86  TNF, 
RaTNF-R55,  and htr-1,  and with  the TNF-R75  agonist 
RaTNF-R75.  As shown clearly in Fig. 3 the induction of 
CD44 (C) as well as the upregulation of MHC class I (D) 
were mediated exclusively through TNF-R55. 
Both TNF Rec~tors Mediate or2 Integrin Induction.  To search 
for a role of TNF-R75 in adhesion, the integrin family of 
adhesion molecules was studied. HUVEC were incubated with 
TNF-cz for various periods of time and the expression levels 
of integrin molecules were analyzed by cytofluorimetry. Some 
of the integrins, such as oe2, orS, a6, o~v, 81, and 83, have 
previously been reported to be expressed on unstimulated 
HUVEC (48-50). TNF-o~ stimulated an upregulation of ol2 
integrin expression (Fig.  4 A). A  slight increase of oe2 ex- 
pression was first seen after 24 h of TNF-cz stimulation and 
the expression reached its maximum after 48-72 h. The up- 
regulation of or2 expression is significant and was reproducibly 
found in three independent experiments. Confirming previous 
reports, a similar upregulation was not seen with other inte- 
grins (51), which indicated that TNF-cx-dependent regula- 
tion is oe2 specific. HUVEC were then stimulated with the 
receptor type-specific agonists Trp32 Thr86 TNF, RaTNF- 
R55, htr-1, and with RaTNF-R75. Interestingly, both TNF 
receptor types were similarly found to mediate c~2 induction 
(Fig.  4, B  and C). 
HL60 Cell Adhesion on Stimulated HUVEC.  Given the 
different aptitudes of TNF-R75 and TNF-R55 to mediate 
the induction of the various cell adhesion molecules, we ex- 
amined whether the two receptor types also differ in their 
capacity to modulate cell adhesion. HUVEC were stimulated 
with the various receptor type-specific agonists. HL60 cells 
that had been prelabeled with methyl-[3H]thymidine were 
overlayed on the HUVEC for 30 min at 37~  Nonadherent 
HL60 cells were removed in a precalibrated centrifugation 
step and the bound HL60 cells quantitated. In the initial se- 
ries of studies (Fig. 5) the optimal concentrations of TNF-ot, 
Trp32  Thr86  TNF,  RaTNF-K55,  htr-1,  and RaTNF-K75 
needed to achieve adhesion after 6 h of treatment of HUVEC 
were determined. It was found that the adhesion induced by 
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Figure  4.  Cytofluorimetric 
profiles of cx2 integrin expression 
in HUVEC.  HUVEC were sti- 
mulated  for  various  periods of 
time with 10 ng/ml TNF-ot and 
stained with anti-human ~x2 in- 
tegrin mAb, followed by PE-con- 
jugated goat anti-mouse Ig. (,4) 
a2  integrin  expression  in  un- 
stimulated (unst) HUVEC and in 
HUVEC after 48 and 72 h TNF-o~ 
stimulation. (B) HUVEC stimu- 
lated  72  h  with  TNF-R55 
agonists Trp32  Thr86  TNF (10 
ng/ml) and htr-1 (10/~g/ml).  (C) 
HUVEC stimulated with TNF- 
R75  agonist  RaTNF-R75  (1 
gg/ml).  Relative  cell  numbers 
(vertical) and fluorescence inten- 
sity (logarithmic scale, horizontal) 
are presented.  The bar indicates 
the position of the control peak. 
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Figure 5.  HL60  cell adhesion  on HUVEC. HUVEC in culture were 
incubated 6 h with various  concentrations  of (tl) TNF-ol ([]) or Trp32 
Thr86 TNF (ll), and (B) htr-1 mAb (0), RaTNF-R55 (A), RaTNF-R75 
(O), and the nonagonistic  utr-1 mAb (&). After incubation, HUVEC 
cultures were washed  with medium and overlayed  with 200/~1 methyl- 
[3H]thymidine-labeled  HL60 cells (10  ~  cells/ml). Adhesion  was performed 
for 30 min at 37~  NonspecificaUy  bound  cells  were removed  by calibrated 
centrifugation.  Bound  HL60  cells  were harvested  and bound  radioactivity 
was counted. The mean of triplicates and standard deviation are given. 
TNF-ol could be mimicked by Trp32  Thr86 TNF despite 
a small difference in specific activity (Fig. 5 A). These findings 
were also confirmed when HUVEC were stimulated with 
RaTNF-R55 and with htr-1 (Fig. 5 B). No significant differ- 
ences were seen among these TNF-R55 agonists. In contrast, 
TNF-R75 triggering resulted in little or no induction of adhe- 
sion after 6 h  stimulation. These findings were confirmed 
by microscopic inspection of the various cell culture adhe- 
sion assays. Similar results were obtained when U937  or 
MOLT-4 cells were used instead of HL60 cells for the adhe- 
sion assays (data not shown). 
To investigate the time dependence of the induction of cell 
adhesion, HUVEC were treated for up to 96 h with the same 
optimal  concentrations  of TNF-ot,  Trp32  Thr86  TNF, 
RaTNF-R55, htr-1, and RaTNF-R75, and cellular adhesion 
assays were performed as before with HL60 cells. It was found 
consistently in three independent experiments (Fig.  6) that 
a first phase  of adhesion occurred within 24 h stimulation 
when HL60 adhesion was strongly induced through TNF- 
R55, whereas stimulation through TNF-R75 did not lead 
to any increased adhesion above background levels. In a later 
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Figure 6.  Time  dependence  of  HL60  eeU adhesion  on activated  HUVEC. 
HUVEC in culture were stimulated  for various  periods of time with op- 
timal concentrations  (see Fig. 5) of TNF<x (17), Trp32 Thr86 TNF (M), 
htr-1 mAb (A), RaTNF-R75 (A), and the nonagonistic  utr-1 control  mAb 
(O). HL60  adhesion  assay  was performed  as described  in Fig. 5. The mean 
of triplicates and standard deviation are given. 
phase, beginning 24 h after the start of cell stimulation, weak 
adhesion of HL60 cells also was induced. This late adhesion 
was at a much lower but still significant level. Interestingly, 
this late adhesion was observed after stimulation through both 
TNF-K55 and TNF-K75. 
TNF-R55 Controls NF-KB Activation.  TNF-ot is a strong 
activator of the transcription nuclear factor KB, NF-KB (52, 
53).  Furthermore, as a common feature,  ~cB elements are 
known to be present in the regulatory flanking sequences 
of the ICAM-1, E-selectin, VCAM-1, and MHC class I genes 
(54-59). NF-gB has been found to be involved in MHC class 
I expression (59). The possible correlation between the con- 
trol of the adhesion molecules by TNF-R55 and NF-KB acti- 
vation was therefore investigated. HUVEC were stimulated 
for 15  min under predetermined optimal conditions with 
TNF-o~, and with the receptor type-specific agonists. Nu- 
clear extracts were prepared from these cells and analyzed in 
an EMSA, performed using a labeled NF-KB-specific oligo- 
nucleotide probe. As shown in Fig. 7 A, NF-~cB was acti- 
vated exclusively through TNF-K55 and not through TNF- 
R75, which parallels the ICAM-1, E-selectin,  and VCAM-1 
induction through TNF-R55. As a specificity control, a similar 
experiment was performed using the HL60 cell line. The HL60 
cells were stimulated 15 min with TNF-~x and various receptor 
type-specific agonists.  The  results  presented  in  Fig.  7  B 
confirmed the findings with the HUVEC, since TNF-R55 
controls NF-KB activation also in HL60. 
Discussion 
Among the factors that control the binding of leukocytes 
to activated endothelium, TNF-oL may be one of the most 
important. The role of TNF-oe in cell adhesion has been in- 
vestigated in a number of studies.  For example,  melanoma 
cell adhesion to HUVEC has been reported to be induced by 
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HUVEC and HL60 cells analyzed by 
electrophoretic  mobility  shift assay. (A) 
HUVEC in culture  were  stimulated 15 
min with 10 ng/ml TNF-c~, 10 ng/ml 
Trp32 Thr86 TNF  (MUT:FNF), 10 
#g/ml  htr-1 mAb, 1 /zg/ml RaTNF- 
R75,  1 #g/ml  RaTNF-K55, and  1 
#g/ml  utr-1 mAb. Nuclear extracts 
were incubated 45  min with  a 32p. 
labeled oligonucleotide  containing the 
NF-KB  binding site. As control, nuclear 
extracts were also incubated with a la- 
beled oligonudeotide  containing a mu- 
tated NF-r,B  binding site. (B) HL60  cells 
were incubated 30 min with 5/zg/ml 
htr-9 mAb, 1 #g/ml RaTNF-K75, 10 
and 0.4 nM TNF-c~, 10 and 0.4 nM 
Trp32  Thr86 TNF, and  1  #g/ml 
RaTNF-K55. Nuclear  extracts were  in- 
cubated 45 min with the same oligo- 
nucleotide probes as  used for  the 
HUVEC. The specific  NF-KB  bands are 
indicated by arrows in the autoradio- 
graphs. 
TNF-ct (15). In HUVEC culture, the TNF-ct-stimulated cell 
adhesion has been found to correlate with the induction of 
several cell adhesion molecules such as ICAM-1, E-selectin, 
and VCAM-1 (reviewed in references 20 and 60). Several studies 
have reported significant reduction of cell adhesion when en- 
dothelial cells were treated with blocking antibodies directed 
against these three adhesion molecules (61). In our own studies, 
the adhesion of HL60 cells to HUVEC was strongly induced 
by TNF-ol  treatment  within  a few hours,  reached  a max- 
imum after 6-8 h,  then gradually decreased. This adhesion 
phenomenon was mediated by TNF-R55 exclusively.  After 
prolonged stimulation  through  TNF-R55  for >24-48 h,  a 
weak cell adhesion persisted.  This latter adhesion phenomenon 
interestingly  also  could  be  triggered  through  TNF-R75, 
demonstrating that both TNF receptor types are functional 
and mediate signals in HUVEC. The exclusive role of TNF- 
R55 in the early and strong induction  of cellular adhesion 
correlates  with  the  induction  of ICAM-1,  E-selectin,  and 
VCAM-1 expression through TNF-R55, whereas TNF-R75- 
mediated signals did not influence the expression of these three 
molecules. The finding that TNF-R55, but not TNF-R75, 
mediated TNF-ct-induced adhesion is consistent with previous 
reports describing the modulation of ICAM-1 and E-selectin 
on HUVEC  after stimulation  with  the TNF-R55-spedfic 
htr  mAb (62) and in keratinocytes that express only TNF- 
R55  (31). 
It is  a common feature of the  ICAM-1,  E-selectin,  and 
VCAM-1 gene promoter sequences to contain  ~cB elements 
that are thought to be important for their regulation (54-58). 
It  is  an  interesting  parallel  that  NF-xB  in  HUVEC  is 
specifically activated through TNF-R55, which is consistent 
with the exclusive role of TNF-R55  in TNF-ct-dependent 
NF-KB activation reported in other cell systems (32, 33). The 
parallel between NF-KB activation and regulation of expres- 
sion through  xB elements suggests that NF-KB might play 
a critical  role in  the control of cell adhesion  to HUVEC. 
However, other control mechanisms in addition to the NF- 
KB pathway must exist, because ICAM-1 is already expressed 
on unstimulated HUVEC, whereas E-selectin and VCAM-1 
appear only after TNF-ot stimulation.  Moreover, these mol- 
ecules show different patterns of induction kinetics.  E-selectin 
is very transiently induced, whereas ICAM-1 and VCAM-1 
have similar induction kinetics. Additional factors therefore 
must play a role in the TNF-ct signal transduction pathway 
eliciting  adhesion.  These factors appear to be under TNF- 
R55 control, because stimulation  through TNF-R55  gives 
similar expression patterns as those seen after TNF-o~ treat- 
ment  interacting  with  both receptor  types. 
The adhesion molecules involved in the weak late adhe- 
sion found equally after TNF-R55 and TNF-R75  stimula- 
tion have not been identified.  The integrin  adhesion mole- 
cules, also called very late antigens (reviewed in reference 63) 
might be candidates.  Previous reports described the regula- 
tion of o~1, ct6, and/~3 integrins in HUVEC by TNF-c~ with 
or without IFN-3, cooperation (51, 64-66). These responses 
required a minimum of 24 h of TNF-ot exposure and reached 
a maximal  level between 48 and 72 h.  The c~2 integrin  in 
HUVEC in the present study was reproducibly induced after 
48-72 h of TNF-ct stimulation.  A further parallel  induction 
is provided by the fact that both TNF receptor types simi- 
larly mediated the c~2 induction and the weak late adhesion, 
and integrins thus might be envisioned to play a role in late 
adhesion.  However, while or2 associated with  the B1 inte- 
grin is known to bind to collagen and laminin (63), its role 
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recent study, cz2 mRNA and protein in human endothelial 
ceUs were found not to be affected by TNF-c~ (66); the in- 
crease in c~2 staining upon TNF-c~ stimulation thus might 
reflect a change in conformation, or an association with a 
different cell surface component, leading to an increased re- 
activity with the antibody rather than a higher expression 
level Integrins have been shown, under an appropriate stimuli, 
to be able to change their conformation (reviewed in refer- 
ence 63). 
Similar to 1CAM-l, E-selectin, and VCAM-1, the CD44 
adhesion molecule on HUVEC is upregulated after prolonged 
TNF-ol stimulation through TNF-R55. The F10-44-2 anti- 
body (63) used to detect CD44 recognizes a constant part 
of the various differentially spliced forms of CD44 (67). CD44 
is known to be a receptor of several ligands including col- 
lagen and hyaluronate. It has been shown to play a role in 
T  cell activation (reviewed in reference 68) and metastatic 
properties of certain tumor cells (67), but its functional role 
in endothelial cells is largely unknown. However, the present 
findings establish distinct activities of TNF-R55 and TNF- 
R75 in HUVEC and point to a pivotal role of TNF-R55 
in TNF-c~-induced cell adhesion to the endothelial cell layer, 
and thus in leukocyte migration and extravasation in sites 
of inflammation and tissue injury. 
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